Subcutaneous · GIP agonist
NNC0480-0389
7 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
7
Active
0
Recruiting
0
Completed
7
Sites
132
Countries
12
Endpoints
62
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
6
Phase 2
1
Trials by status
Completed
7
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
34
Cardiometabolic biomarkers
18
Weight & body composition
6
Glycemic / diabetes
4
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
15
CmaxSafety/PK
14
Treatment-emergent AEs (any)Safety/PK
5
HbA1c, changeGlycemic
2
Fasting glucose, changeGlycemic
2
Body weight, absolute change (kg)Weight
2
Body weight, % changeWeight
2
Waist circumference, changeWeight
2
Systolic BP, changeBiomarker
2
Total cholesterol, changeBiomarker
2
HDL-C, changeBiomarker
2
LDL-C, changeBiomarker
2
VLDL, changeBiomarker
2
Triglycerides, changeBiomarker
2
Free fatty acids, changeBiomarker
2
ApoB, changeBiomarker
2
hs-CRP, changeBiomarker
2
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
7 of 7